Travere Therapeutics Quarterly Balance Sheet
NASDAQ: TVTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Travere Therapeutics financial position
As of Jun 30, 2026, Travere Therapeutics reported total assets of $799.4 million, up 43.9% from a year earlier against total liabilities of $774.8 million. Shareholders' equity stood at $24.5 million, or 3.1% of assets. The company held $117.7 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 4.05, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Travere Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 117.73M | 78.36M | 93.03M | 110.93M | 75.15M | 61.90M | 58.53M | 36.41M | 32.29M | 43.25M | 58.18M | 144.24M |
| Short-Term Investments | 175.91M | 130.59M | 145.38M | 138.66M | — | — | — | 218.95M | 221.65M | 241.36M | 248.64M | 212.63M |
| Receivables | 80.64M | 87.30M | 80.13M | 82.98M | 38.72M | 34.38M | 27.12M | 25.17M | 24.47M | 22.73M | 21.18M | 14.57M |
| Inventory | 40.05M | 37.05M | 36.16M | 37.55M | 37.68M | 38.01M | 41.86M | 42.88M | 42.98M | 42.31M | 9.41M | 20.77M |
| Total Current Assets | 615.14M | 392.68M | 437.56M | 371.11M | 379.57M | 374.17M | 416.70M | 324.74M | 368.98M | 481.08M | 616.77M | 686.23M |
| Property, Plant & Equipment | 3.23M | 3.63M | 4.02M | 4.32M | 4.56M | 4.85M | 5.34M | 6.16M | 6.58M | 6.94M | 7.48M | 8.00M |
| Goodwill | — | — | — | 800.00K | 800.00K | 800.00K | 800.00K | 800.00K | 800.00K | 800.00K | 800.00K | 800.00K |
| Intangible Assets | 131.52M | 110.04M | 113.87M | 109.44M | 105.61M | 103.82M | 103.97M | 104.20M | 105.17M | 101.18M | 104.44M | 106.90M |
| Long-Term Investments | 195.53M | 55.73M | 84.38M | 4.95M | — | — | — | 22.08M | 71.45M | 156.43M | 260.04M | 277.77M |
| Total Assets | 799.36M | 555.19M | 605.19M | 538.58M | 555.31M | 548.80M | 594.13M | 504.41M | 551.12M | 663.55M | 788.91M | 832.85M |
| Accounts Payable | 7.50M | 12.91M | 24.80M | 18.23M | 19.13M | 15.37M | 23.53M | 23.20M | 25.84M | 16.73M | 41.67M | 24.74M |
| Total Current Liabilities | 152.03M | 125.44M | 159.90M | 135.07M | 189.54M | 182.46M | 200.75M | 190.04M | 121.27M | 173.23M | 177.91M | 139.43M |
| Total Liabilities | 774.84M | 456.46M | 490.36M | 465.02M | 522.56M | 515.98M | 535.05M | 534.86M | 535.97M | 589.48M | 588.10M | 553.08M |
| Shareholders' Equity | 24.52M | 98.73M | 114.83M | 73.56M | 32.75M | 32.82M | 59.08M | -30.45M | 15.15M | 74.07M | 200.81M | 279.77M |
| Retained Earnings | -1.54B | -1.51B | -1.47B | -1.48B | -1.50B | -1.49B | -1.45B | -1.39B | -1.33B | -1.26B | -1.13B | -1.04B |
| Net Cash (Debt) | 293.64M | 208.95M | 238.42M | 249.59M | 75.15M | 61.90M | 58.53M | 255.35M | 253.94M | 284.61M | 306.81M | 356.87M |
| Shares Outstanding | 94.17M | 92.40M | 90.92M | 89.46M | 89.10M | 88.79M | 87.45M | 77.91M | 76.46M | 76.11M | 75.37M | 75.11M |
This table shows 12 quarterly periods of Travere Therapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow TVTX's reporting calendar. What is a balance sheet?